Please login to the form below

Not currently logged in

Lundbeck presses on with cost-saving programme

Will cut up to 200 business services jobs in Europe
Lundbeck headquarters

Danish pharma company Lundbeck is to shed 180 to 200 jobs in Europe in a restructure of its European business services functions.

The move, which is part of its ongoing Fit-for-the-Future project, will see a new business service centre established in Poland follows the news of 50 job losses within its commercial operations this year and some 600 last year.

The latest cuts will have to wait for the completion of consultation processes with relevant work councils but are likely, Lundbeck said, to take effect between 2014 and 2015.

Chief financial officer Anders Götzsche said: "Lundbeck remains fully committed to our long-term strategy and over the years we have taken decisive steps in order to improve our organisational efficiencies and our ability to succeed in a changing environment.

"We are very aware that these initiatives affect many employees and we will strive to mitigate any negative effects these might have".

The firm hopes its Fit-for-the-Future project will bring in savings of more than 500m Danish krone (€67m) a year from 2016, by reducing complexity, increasing organisational efficiency and decreasing spending on less critical activities.

Lundbeck said the changes were part of a drive to improve its product launch capabilities by simplifying its commercial structure, increasing alignment across countries and improving competencies and investing in areas like market access.

The company has set aside 200m Danish krone to pay for the latest reorganisation, and any other changes under the programme, and will book the charge in the third quarter of this year.

Nevertheless, Lundbeck has increased its 2013 revenue projections slightly from 14.6 - 15bn Danish krone to 14.8 - 15.2 bn Danish krone, but said earnings before interest and taxes would take a hit from its recent anti-competition fine and, at best, would be flat compared to 2012.

The company was hit with a €93.8m penalty in June after the European Commission concluded it had collaborated with several other companies to delay the entry of generic competition for its big-selling antidepressant Celexa/ Cipramil (citalopram).

Article by
Dominic Tyer

1st October 2013

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...